<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110824</url>
  </required_header>
  <id_info>
    <org_study_id>OVERCOME</org_study_id>
    <secondary_id>2007-006604-38</secondary_id>
    <secondary_id>FIS EC07/90211</secondary_id>
    <nct_id>NCT01110824</nct_id>
  </id_info>
  <brief_title>Prevention of Left Ventricular Dysfunction During Chemotherapy</brief_title>
  <acronym>OVERCOME</acronym>
  <official_title>Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' objective is to assess the efficacy of the combined treatment with
      enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in
      patients with hematological malignancies submitted to intensive chemotherapy with potential
      cardiotoxicity.

      The hypothesis is that these drugs administered during chemotherapy may prevent left
      ventricular systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of patients with hematological malignancies has greatly improved in the last
      years with the use of new chemotherapeutic drugs and regimens at the cost of significant
      adverse events such as cardiac toxicity. Asymptomatic left ventricular systolic dysfunction
      limits the specific treatment of the patients and their long-term survival, since a
      significant proportion of them will relapse within 5 years after front-line therapy and will
      require further salvage treatment, including hematopoietic stem-cell transplantation in most
      instances.

      Angiotensin-converting enzyme inhibitors (ACEIs) have showed to have preventive effects
      against chemotherapy-induced cardiotoxicity in animal models, and in patients with early
      cardiotoxicity. Carvedilol prevent free radical release, mitochondrial dysfunction,
      apoptosis, and dilated cardiomyopathy in animals treated with anthracyclines, and have shown
      promising results in preventing chemotherapy-induced left ventricular dysfunction in
      patients.

      As demonstrated in post-infarction patients, the combined treatment with an ACEI and
      carvedilol could have additive effects to prevent LV dysfunction in patients with
      hematological malignancies at high risk of cardiac toxicity. Therefore, we designed the
      OVERCOME (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in
      patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
      study, a prospective, randomized trial to evaluate the combined effect of enalapril and
      carvedilol on the prevention of left ventricular dysfunction in patients with malignant
      hemopathies undergoing intensive chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiography and by cardiac magnetic resonance imaging (CMR).</measure>
    <time_frame>6 months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of death, heart failure or LV systolic disfunction (LVEF&lt;45%)</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of genetic polymorphisms involved in chemotherapy-induced cardiotoxicity</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value for cardiac toxicity of troponin I and BNP</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right and left ventricular volumes measured by CMR</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis by diagnosis (acute leukemia vs. other malignant hemopathies submitted to autologous peripheral blood stem cell transplantation), and positive biomarkers (TnI, BNP).</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of an absolute decrease in LVEF&gt;10 percent units associated with a decline below its normal limit of 50%</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of LV dysfunction as assessed by the measurement of the LV strain, and of diastolic dysfunction measured by echo-Doppler</measure>
    <time_frame>6 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Precursor-cell Lymphoblastic Leukemia-Lymphoma</condition>
  <condition>Lymphoid Neoplasm</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <condition>Autologous Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Enalapril and carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm without intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril and carvedilol</intervention_name>
    <description>Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID</description>
    <arm_group_label>Enalapril and carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 18-70 years old

          -  Sinus rhythm

          -  Normal LVEF (&gt;=50%)

          -  Patients recently diagnosed of acute leukemia to be submitted to intensive
             chemotherapy or

          -  Patients with other hemopathies submitted to autologous peripheral blood stem cell
             transplantation

          -  Signed informed consent

        Exclusion Criteria:

          -  Congestive heart failure

          -  LVEF&lt;50%

          -  Coronary artery disease,

          -  significant valvulopathy or myocardiopathy

          -  Renal failure (MDRD&lt;30)

          -  Liver failure

          -  Ongoing or expected need to be treated with angiotensin-converting enzyme inhibitors
             (ACE-i),angiotensin II receptor blockers (ARB) or beta-blockers

          -  Prior allergy to ACEI or ARB

          -  Systolic blood pressure &lt;90 mmHg

          -  Asthma

          -  Auriculoventricular (AV) block or sinus bradycardia (HR&lt;60 bpm)

          -  Persistent atrial fibrillation

          -  Need to be treated with Class I antiarrhythmic drugs

          -  Pregnancy

          -  Inability or unwillingness to give unformed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Bosch, M.D., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic, University of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bosch X, Esteve J, Sitges M, de Caralt TM, Domènech A, Ortiz JT, Monzó M, Morales-Ruiz M, Perea RJ, Rovira M. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail. 2011 Aug;17(8):643-8. doi: 10.1016/j.cardfail.2011.03.008. Epub 2011 May 6.</citation>
    <PMID>21807325</PMID>
  </reference>
  <results_reference>
    <citation>Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10.</citation>
    <PMID>23583763</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Xavier Bosch</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>ventricular dysfunction</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>precursor-cell lymphoblastic leukemia</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>lymphoma</keyword>
  <keyword>ejection fraction</keyword>
  <keyword>Autologous hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

